BCRX Weekly View of Triangle Pattern #WallStreetBetsShort % of Shares Outstanding (Jan 15, 2021) 17.53% From Yahoo Finance
WallStreetBets Link
www.reddit.com
www.reddit.com
Get Ready...
BCRX trade ideas
BCRX Monthly View of Triangle Pattern #WallStreetBetsShort % of Shares Outstanding (Jan 15, 2021) 17.53% From Yahoo Finance
WallStreetBets Link
www.reddit.com
www.reddit.com
Get Ready...
BCRX VERY LONGFavorite stock here. Fundamentals are outstanding. Excited for Q4 earnings and more importantly Q1. Future $100 stock in 5 years if execution on Bero and Factor D follow through.
$BCRXEntry price: 8.27
Fundamentals:
- Sector: Medical - Biotech
- EPS % Chg (Last Qtr): 24%
- EPS % Chg (Previous Qtr): 24%%
- 3 Year EPS Growth Rate: 0%
- EPS Est % Chg (Current Yr): 0%
- Sales % Chg (Last Qtr): 243%
- Sales % Chg (Previous Qtr): 98%
- 3-Year Sales Growth Rate: 25%
- Annual Pre -Tax Margin: -223%
18-65% gain potential It is my technical view, not a comment on the fundamental..!
I can make you confused you by a crowded messy chart, but I would rather simple effective presentations..!
BCRX - keep trading the pullbackNote from BoA Global Research: "BCRX announced a royalty purchase agreement with RPRX and a credit loan agreement with Athyrium. BCRX will receive an upfront $125mn cash from RPRX, in exchange for 8.75% sales-based royalties up to $350mn annual sales, 2.75% royalties between $350mn-$550mn and tiered revenues outside of key territories for the recently-approved Orladeyo in preventing hereditary angioedema (HAE) attacks. The agreement also grants RPRX 1% sales royalty on its oral Factor D inhibitor BCX9930 that’s currently being evaluated in treating paroxysmal nocturnal hemoglobinuria (PNH). BCRX will also draw $125mn from the $200mn credit facility with Athyrium to repay outstanding ~$44mn debt with MidCap Fin. Trust and support its ongoing launch of Orladeyo and R&D development. We positively view today’s updates, as the agreements strengthen the company’s balance sheet and remove the near term need for dilutive financing. It also extends its cash runway meaningfully and allows the company to focus on advancing the early-stage BCX9930 program."
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), FirBCRX: BioCryst Pharmaceuticals, Inc.
2020-12-03 20:45:00
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
$BCRX BioCryst Pharmaceuticals, Gap fill Trade to $7.20 BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
Looks like breakoutLook at the trend line which is clearly broken on upside> need to continue the upward momentum.
BCRX potential big moveMultiple bullish indicators across all time horizons. Exiting cup and handle with bullish trends and CS patterns. Support between 4.9-5. First target 5.82 followed by potential short opportunity as it tests support at 5. Following previous year's market structure and price action, backed by upcoming announcements regarding product release and test results, long target 16+.
Keep an eye on RSI and 8 hour EMA/MA cross as price action historically respects both pretty strictly. Dragonfly Doji's also a strong indicator for big moves.
*This is a personal idea and not a recommendation
BCRX Harmonic GartleyBullish Harmonic Gartley on 2-day chart is pretty strong pattern for the bulls.
BioCryst Pharna is going to search lower for support ($3.25?)Broke under the 20dma, and I think this has further to fall. The Short Float being this high with this much institutional activity has me thinking a big fish is dragging this down. Will be important to watch the float disappear which could really move this thing. Till then I think it is a short.
$BCRX - Guess what's happening when the price is above MA20?Positive trigger as mentioned yesterday, 4.66
Not for any advise
Just a one more viewpoint.
